HF 4852
  • Introduced
    Apr 07, 2026
  • Passed House
  • Passed Senate
  • Became Law
HF 4852
Minnesota House Bill
Did you know we offer free bill tracking in Congress and 50 states, AI tools to streamline your work, and a great mobile app? Sign up here
Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.
Last Action See all actions
House • Apr 07, 2026: Introduction and first reading, referred to Health Finance and Policy
Latest Bill Text See all bill texts
Introduction

Summary

Comments on HF 4852

Tweets

Whip Lists

Sponsors
Votes
Looks like there aren't any voting records available at this moment.
Actions
  • Apr 07, 2026 | House
    • Introduction and first reading, referred to Health Finance and Policy
Bill Texts
Documents
Looks like we don't have any documents available at this moment.
Sources